Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Morning or evening workout: which melts liver fat best?

NCT ID NCT07386665

Disease control Sponsor: Universidad de Almeria Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether exercising in the morning or evening makes a bigger difference in reducing liver fat for postmenopausal women with fatty liver disease. Sixty-three women will be placed into morning exercise, evening exercise, or a no-exercise group for 12 weeks. Researchers will measure liver fat, heart health markers, and gut bacteria changes to find the best timing for exercise benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 63 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 45-75 years, postmenopausal for at least two years (stage +1a) * Body Mass Index (BMI) \> 25 and \< 40 kg/m² * Diagnosed hepatic steatosis (via ultrasound hyperechogenicity, FibroScan CAP score \>280, or histological confirmation) * Sedentary lifestyle (no regular structured exercise) * Willingness to be randomized and adhere to study procedures, including all assessments and visits * Sufficient Spanish proficiency to understand and follow study instructions * Consent to store biological samples for future research * Participants should have a healthy circadian rhythm Exclusion Criteria: * Contraindications for MRI (e.g., claustrophobia, pacemaker, metal implants) * History of major cardiovascular, endocrine, neurological, or kidney disease, or any clinical abnormalities (to be judged by the study physician) * First-degree family history of sudden cardiac death * Alcohol or substance abuse * Psychiatric, psychotic, eating, or sleep disorders (to be judged by the study physician) * Prior bariatric surgery, diagnosed HIV/AIDS, or inflammatory/autoimmune diseases * Cancer or any medical condition where exercise is contraindicated (to be judged by the study physician) * Recent or unstable metabolic conditions (e.g., diabetes, recent medication changes, or use of drugs affecting metabolism) * Recent (\<3 months) use of antibiotics, statins, glucocorticoids, hormonal therapies, amiodarone, or myelosuppressive agents * Participation in weight-loss programs or special diets (e.g., ketogenic, high-carb) * Shift workers or caregivers with frequent nocturnal disruptions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiometabolic diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiometabolic diseases Exercise Metabolic dysfunction-associated steatotic liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Universidad de Almería

    Almería, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.